Uphulo olutsha lwezonyango olubizwa ngokuba yimpirha ejoliswe kuyo luyafumaneka kumdlavuza wemiphunga. Ngokungafani ne- chemotherapy yendabuko, ezi zonyango zijolise kwiiprotheni kumaseli omhlaza okanye iithagethi eziqhelekileyo eziye zatshitshiswa yi-tumor xa zizama ukukhula. Ngenxa yoko, bavame ukuba nemiphumo emibini engaphantsi kwemiyeza enokusetyenziswa ngumhlaza.
Okwangoku, oku kusetyenziswa ngokubanzi kwisigaba sesi-3 no-4 umhlaza womphunga ongazange uphendule kwenye iyeza . Ezi zimbini zonyango eziqhelekileyo zibandakanya:
ITarceva (erlotinib)
Ummandla wamaseli omhlaza wamaphaphu uhlanganiswe ngeprotheni ebizwa ngokuba yi- epidermal growth receptor (EGFR) , esinceda iiseli zihlukane. I-Tarceva isebenza ngokungavumeli i-EGFR ukuba ichaze iiseli zomhlaza ukuba zikhule. Ngoxa unokuba luncedo kwiintlobo ezininzi zezigulane, kuboniswe ukuba kunokwenzeka ukuba kusebenze abo bangakhange bavume okanye kubafazi abaselula. Ukunikezelwa njengepilisi yemihla ngemihla, iziphumo eziqhelekileyo eziqhelekileyo zibuhlungu besikhumba esifana ne-acne, kunye nehudo. Nangona ukukhwabanisa kwesikhumba kunokuba yinkathazo yokuziqhenqa, abo bahlakulela i-erlotinib banokuthi baphendule kunyango.
Xylori (crizotinib)
Phakathi ko-3 no-5% wabantu abanomdlavuza omninzi wamangqamuzana omnxeba unomdla owaziwa ngokuba yi-ALK-EML4 ye-gene rearrangement.
Kubantu abanolu tshintsho, i-crizotinib yamachiza ifunyenwe ukwandisa ukuqhubekeka kokusasazeka. Njengoko i-erlotinib, i-crizotinib kaninzi inempembelelo engaphantsi kwendalo yendalo kwaye ingathathwa njengemithi yomlomo. Ngokufanayo, oku kuguquka xa kunokwenzeka ukuba kufumaneke kubantu abangakhange bavume.
Ngelixa i-crizotinib yandisa ixesha lokuqhubekeka lokungahlali, ukunyamezela kuqhubeka ngexesha. Ngombulelo amayeza amasha afunyenwe kwiimvavanyo zonyango ezingasebenza xa ukulwa nokulwa ne-crizotinib kukhula, kwaye kuthemba ukuba ngokuhamba kwesikhathi, umdlavuza we-ALK-positive ungaphathwa njengesifo esingapheliyo, njengesifo sikashukela.
Funda kabanzi malunga nomhlaza we-ALK-positive kule nqaku
Ukususela ngo-2014, i- crizotinib iphinde ivunyiwe kubantu abane-ROS1 . Njengabo abaneenguquko ze-ALK, crizotinib yandisa ukuqhubeka kokusinda-mahhala.
Amanye amayeza ahlalutyo kwiimvavanyo zeclini kubantu abaye baxhatshazwa kumachiza okuguquka kwe-EGFR kunye nokuguqulwa kwe-ALK, kunye nezinye "iinguqu ezijoliswe kuyo" zifundiswa.
Ukuhlolwa kwe-Genetic (i-Molecular Profiling) Kwi-Cancer Cancer
Ngoku uvakalelwa kukuba wonke umntu ophethe imiphunga yamaphenyasoma ephambili (kunye nabanye abantu abane- squamous cell cell lung cancer , ikakhulu abo bangakhange bavume) kufuneka bavavanyelwe ukuguqulwa kwemizimba kunye nokuxhamla kwamathumba abo okuya kuphendula kumachiza atshagethiweyo. Nangona kunjalo, abantu abaninzi abanokuthi babe nefuthe ngenxa yolu tshintsho kwaye ngenxa yoko abaviwa kuba mayeza, abafumani inzuzo yovavanyo.
Funda kabanzi malunga noprofayili wee-molecular yomdlavuza wamaphaphu kule nqaku
> Imithombo:
> I-American Cancer Society. Iipilithi ezijoliswe. 08/13/15.
> INational Cancer Institute. I-Can-Small Cell Lung Cancer (PDQ). Uhlobo lokuPhepha lweMpilo. Ukuhlaziywa 05/12/15.